Arctoris has opened its new global headquarters and state-of-the-art research and development (R&D) facility in Oxford, UK. Housing the company’s proprietary technology and providing space for its rapidly growing commercial and scientific teams, the facility will enable Arctoris to continue to support its research partners around the world with its structured, automated approach to drug discovery.
The new scientific facility contains its next-generation, fully automated platform developed by the drug discovery professionals, engineers and roboticists. The platform efficiently generates reproducible data from biochemical, cell-based and molecular biology assays. The rapid turnaround enables shorter cycle times – and therefore more design-make-test-analyze iterations – for their drug discovery partners. This end-to-end robotic platform provides biotechnology companies, pharmaceutical corporations and academic centers with cost-effective and reproducible drug discovery data – all through an online portal that streamlines experiment planning, ordering, tracking and data analysis.
"Investing in new global headquarters and greatly enhanced R&D facility in our home city of Oxford, UK, an internationally-renowned center of scientific excellence, demonstrates our continued commitment to delivering the highest standards of data available to our partners,” Martin-Immanuel Bittner MD DPhil, Chief Executive Officer and Co-Founder of Arctoris, said. “This state-of-the-art home for our next-generation robotic platform enables our growing team of experts to provide scientists across the globe with access to reproducible data through a rapid and fully-validated approach to drug discovery."